{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:51:36Z","timestamp":1791669096170,"version":"4.3.4"},"reference-count":32,"publisher":"Informa UK Limited","issue":"1","funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R03 DA043613"],"award-info":[{"award-number":["R03 DA043613"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychoactive Drugs"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1080\/02791072.2020.1802087","type":"journal-article","created":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T07:13:00Z","timestamp":1596525180000},"page":"47-54","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":23,"title":["Descriptions of Gabapentin Misuse and Associated Behaviors among a Sample of Opioid (Mis)users in South Florida"],"prefix":"10.1080","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5001-7391","authenticated-orcid":false,"given":"Mance E.","family":"Buttram","sequence":"first","affiliation":[{"name":"Center for Applied Research on Substance Use and Health Disparities, Nova Southeastern University, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Kurtz","sequence":"additional","affiliation":[{"name":"Center for Applied Research on Substance Use and Health Disparities, Nova Southeastern University, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,8,4]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1086\/591699"},{"key":"e_1_3_3_3_1","unstructured":"Alabama State Board of Health. 2019. Controlled substances list. Accessed February 7 2020. https:\/\/www.alabamapublichealth.gov\/publications\/assets\/controlledsubstanceslist.pdf."},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102752"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1159\/000355268"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11126-016-9421-7"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.15r01821"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.2165\/11536200-000000000-00000"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.107554"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4230"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2019.07.011"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2019.1671943"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/1937586715614171"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.24150\/ajhm\/2019.005"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0700-x"},{"key":"e_1_3_3_16_1","volume-title":"Global appraisal of individual needs \u2013 individual (GAIN-I), version [GVER]: 5.7.6","author":"Global Appraisal of Individual Needs","year":"2016","unstructured":"Global Appraisal of Individual Needs. 2016. Global appraisal of individual needs \u2013 individual (GAIN-I), version [GVER]: 5.7.6. Bloomington, IL: Chestnut Health Systems."},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002396"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1704633"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/10826080500391829"},{"key":"e_1_3_3_20_1","unstructured":"King L. 2020. State-imposed restrictions on gabapentin. Accessed February 7 2020. https:\/\/www.medval.com\/2020\/01\/08\/state-imposed-restrictions-on-gabapentin\/."},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.epirev.a017921"},{"key":"e_1_3_3_22_1","unstructured":"Mincher T. 2018. Gabapentin is a schedule V controlled substance as of July 1 2018. Tennessee Veterinary Medical Association. Accessed January 29 2020. http:\/\/tvmanet.com\/2018\/06\/29\/gabapentin-is-a-schedule-v-controlled-substance-as-of-july-1-2018\/."},{"key":"e_1_3_3_23_1","unstructured":"North Dakota State Board of Pharmacy. 2019. Gabapentin added as a schedule V substance in the North Dakota controlled substanced act. Accessed February 7 2020. https:\/\/nabp.pharmacy\/wp-content\/uploads\/2016\/06\/North-Dakota-Newsletter-June-2019.pdf."},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.2147\/RMHP.S168504"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-017-0595-1"},{"key":"e_1_3_3_26_1","unstructured":"Quintiles IMS Institute. 2017. Medicines use and spending in the U.S.: A review of 2016 and outlook to 2021. Accessed December 4 2019. https:\/\/structurecms-staging-psyclone.netdna-ssl.com\/client_assets\/dwonk\/media\/attachments\/590c\/6aa0\/6970\/2d2d\/4182\/0000\/590c6aa069702d2d41820000.pdf?1493985952."},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2014.13111526"},{"key":"e_1_3_3_28_1","volume-title":"The coding manual for qualitative researchers","author":"Salda\u00f1a J.","year":"2013","unstructured":"Salda\u00f1a, J. 2013. The coding manual for qualitative researchers. Los Angeles, CA: Sage."},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1037\/adb0000337"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2014.14101272"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2019.12.007"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.21897"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.12159"}],"container-title":["Journal of Psychoactive Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/02791072.2020.1802087","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T07:58:00Z","timestamp":1698393480000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/02791072.2020.1802087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,4]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1080\/02791072.2020.1802087"],"URL":"https:\/\/doi.org\/10.1080\/02791072.2020.1802087","relation":{},"ISSN":["0279-1072","2159-9777"],"issn-type":[{"value":"0279-1072","type":"print"},{"value":"2159-9777","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ujpd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ujpd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-02-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}